SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.
COVID‐19
SARS‐CoV‐2
antibodies
antibody‐secreting cells
circulating T follicular helper cells
germinal centres
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
03
2021
revised:
30
04
2021
revised:
08
06
2021
accepted:
08
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Humoral and cellular immunity to SARS-CoV-2 following COVID-19 will likely contribute to protection from reinfection or severe disease. It is therefore important to characterise the initiation and persistence of adaptive immunity to SARS-CoV-2 amidst the ongoing pandemic. Here, we conducted a longitudinal study on hospitalised moderate and severe COVID-19 patients from the acute phase of disease into convalescence at 5 and 9 months post-symptom onset. Utilising flow cytometry, serological assays as well as B cell and T cell FluoroSpot assays, we assessed the magnitude and specificity of humoral and cellular immune responses during and after human SARS-CoV-2 infection. During acute COVID-19, we observed an increase in germinal centre activity, a substantial expansion of antibody-secreting cells and the generation of SARS-CoV-2-neutralising antibodies. Despite gradually decreasing antibody levels, we show persistent, neutralising antibody titres as well as robust specific memory B cell responses and polyfunctional T cell responses at 5 and 9 months after symptom onset in both moderate and severe COVID-19 patients. Our findings describe the initiation and, importantly, persistence of cellular and humoral SARS-CoV-2-specific immunological memory in hospitalised COVID-19 patients long after recovery, likely contributing towards protection against reinfection.
Identifiants
pubmed: 34257967
doi: 10.1002/cti2.1306
pii: CTI21306
pmc: PMC8256672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1306Investigateurs
M Akber
(M)
S Aleman
(S)
L Berglin
(L)
H Bergsten
(H)
N K Björkström
(NK)
S Brighenti
(S)
D Brownlie
(D)
M Butrym
(M)
B J Chambers
(BJ)
M Cornillet
(M)
A Cuapio
(A)
I Diaz Lozano
(I)
L Dillner
(L)
J Emgård
(J)
M Flodström-Tullberg
(M)
A Färnert
(A)
Y Gao
(Y)
H Glans
(H)
J B Gorin
(JB)
J Grip
(J)
A Haroun-Izquierdo
(A)
E Henriksson
(E)
L Hertwig
(L)
S Kalsum
(S)
T Kammann
(T)
E Kokkinou
(E)
E Kvedaraite
(E)
M G Loreti
(MG)
M Lourda
(M)
K J Malmberg
(KJ)
N Marquardt
(N)
C Maucourant
(C)
J Mårtensson
(J)
J Michaëlsson
(J)
J Mjösberg
(J)
K Moll
(K)
P Nauclér
(P)
A Norrby-Teglund
(A)
L M Palma Medina
(LM)
T Parrot
(T)
A Perez-Potti
(A)
B P Persson
(BP)
L Radler
(L)
E Ringqvist
(E)
O Rivera-Ballesteros
(O)
J K Sandberg
(JK)
T Sekine
(T)
E Sohlberg
(E)
T Soini
(T)
M Svensson
(M)
J Tynell
(J)
C Unge
(C)
A von Kries
(A)
D Wullimann
(D)
Informations de copyright
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
Marcus Buggert is a consultant for Oxford Immunotech. All other authors declare no competing interests.
Références
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Sci Rep. 2018 Feb 9;8(1):2729
pubmed: 29426881
Sci Rep. 2021 Jan 28;11(1):2608
pubmed: 33510275
Sci Rep. 2019 Jul 12;9(1):10090
pubmed: 31300682
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
mBio. 2021 Jan 19;12(1):
pubmed: 33468695
Med (N Y). 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Front Immunol. 2012 Apr 17;3:78
pubmed: 22566959
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Virol. 2007 Aug;81(16):8468-76
pubmed: 17553885
Clin Transl Immunology. 2020 Dec 14;9(12):e1224
pubmed: 33343897
Nature. 2008 May 29;453(7195):667-71
pubmed: 18449194
Oxf Open Immunol. 2020;1(1):iqaa003
pubmed: 34192266
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Immunol. 2020 Aug 21;5(50):
pubmed: 32826343
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33479167
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
J Infect Dis. 2010 Dec 1;202(11):1659-66
pubmed: 20979459
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Curr Opin Virol. 2011 Oct;1(4):226-32
pubmed: 22440781
Cell Mol Immunol. 2020 Nov;17(11):1180-1182
pubmed: 32963357
Blood. 2009 Mar 12;113(11):2461-9
pubmed: 18987362
J Infect. 2021 Apr;82(4):e29-e30
pubmed: 33373652
J Exp Med. 2021 May 3;218(5):
pubmed: 33646265
Diagn Microbiol Infect Dis. 2021 Apr;99(4):115300
pubmed: 33388575
Antiviral Res. 2017 Jan;137:82-92
pubmed: 27840203
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Exp Med. 2007 Oct 1;204(10):2473-85
pubmed: 17893201
Eur J Immunol. 2020 Sep;50(9):1283-1294
pubmed: 32910469
J Immunol. 2020 Nov 1;205(9):2437-2446
pubmed: 32878912
J Exp Med. 2007 Jun 11;204(6):1405-16
pubmed: 17535971
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
J Virol. 2008 Sep;82(17):8812-9
pubmed: 18579590
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Immunity. 2021 May 11;54(5):988-1001.e5
pubmed: 33857421
Immunity. 2013 Mar 21;38(3):596-605
pubmed: 23499493
Sci Immunol. 2020 Sep 28;5(51):
pubmed: 32989174